Mattia Rediti

Université libre de Bruxelles (ULB)

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (14)

Collaborators (11)

Laurence Buisseret

Université libre de Bruxelles (ULB)

Gabriele Martelli

Fondazione IRCCS Istituto Nazionale dei Tumori

Christos Sotiriou

Université libre de Bruxelles

Andrea Vingiani

Fondazione IRCCS Istituto Nazionale dei Tumori

Diether Lambrechts

full professor

Serena Di Cosimo

Open University

UNITED KINGDOM

Thomas Guiot

Université libre de Bruxelles

Zena Wimana

Institut Jules Bordet

Alex De Caluwe

Université libre de Bruxelles (ULB)

Danai Fimereli

Université libre de Bruxelles (ULB)

Antonia Martinetti

Fondazione IRCCS Istituto Nazionale dei Tumori

Mattia Rediti

Research Interests

Explore related searches

Contact this professor

Articles (14)

Collaborators (11)

Laurence Buisseret

Gabriele Martelli

Christos Sotiriou

Andrea Vingiani

Diether Lambrechts

Serena Di Cosimo

Thomas Guiot

Zena Wimana

Alex De Caluwe

Danai Fimereli

Antonia Martinetti

How do I reach out?

Meet Kite AI

Mattia Rediti

Research Interests

Explore related searches

Contact this professor

Articles (14)

Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial

Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial

Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Timing evolution of lobular breast cancer through phylogenetic analysis

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

Characterizing CDK12-Mutated Prostate Cancers

Collaborators (11)

Laurence Buisseret

Gabriele Martelli

Christos Sotiriou

Andrea Vingiani

Diether Lambrechts

Serena Di Cosimo

Thomas Guiot

Zena Wimana

Alex De Caluwe

Danai Fimereli

Antonia Martinetti

How do I reach out?

Meet Kite AI